Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

(c) On November 1, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the "Company") appointed Brendan P. Teehan as Executive Vice President, Chief Operating Officer and Head of Commercial and as the Company's principal operating officer. The Company's press release dated November 1, 2021 is attached as Exhibit 99.1.

Mr. Teehan, age 53, joined the Company in July 2018 as Vice President, Insights, Analytics and Commercial Operations. In March 2021, he was promoted to Senior Vice President, Chief Insights and Analytics Officer. Prior to joining the Company, Mr. Teehan served as Vice President, Provider Solutions at TESARO, Inc., a commercial-stage oncology company, from June 2016 to July 2018, and as Vice President, then Senior Vice President, Pharmacy Services at RainTree Oncology, an oral oncology services company, from April 2012 to April 2016. Mr. Teehan earned a Bachelor of Arts in government and international relations from the University of Notre Dame and an M.B.A. from Carnegie Mellon University, Tepper School of Business.

There is no arrangement or understanding between Mr. Teehan and any other person pursuant to which Mr. Teehan was selected as an officer, and there are no actual or proposed transactions between the Company and Mr. Teehan or any related person that would require disclosure under Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
Number       Description

99.1           Press Release dated November 1, 2021

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses